Canada Plasma Fractionation Market Size, Share & Industry Analysis, By Product (Albumin, Immunoglobulin [Intravenous Immunoglobulin {IVIG}, and Subcutaneous Immunoglobulin {SCIG}], Coagulation Factors [Factor IX, Factor VIII, Prothrombin Complex Concentrates, Fibrinogen Concentrates, and Others], Protease Inhibitors, and Others), By Application (Immunology & Neurology, Hematology, Critical Care, Pulmonology, and Others), By End User (Hospitals & Clinics, Clinical Research Laboratories, and Others), and Country Forecast, 2025-2032

The Canada plasma fractionation market size was valued at USD 1.10 billion in 2024. The market is projected to grow from USD 1.12 billion in 2025 to USD 1.50 billion by 2032, exhibiting a CAGR of 4.28% during the forecast period.

Plasma fractionation involves the separation of human plasma into its components that are used for various therapeutic purposes. The Canadian plasma fractionation market is projected to grow at a notable pace, driven by rising demand for plasma-derived therapies, increasing domestic collection initiatives, and investments in local fractionation capacity.

Furthermore, the market is dominated by Octapharma AG, Grifols S.A., and CSL Behring. The leading positions of plasma fractionation companies in the Canadian market are supported by their agreements with regulatory bodies and the expansion of plasma collection centers in the country.

MARKET DYNAMICS

MARKET DRIVERS:

Expansion of Domestic Plasma Collection & Self-Sufficiency Strategy to Propel Market Growth

Canada is pursuing higher domestic plasma collection and fractionation capacity to reduce dependence on foreign-sourced plasma and finished plasma-derived medicinal products. This is one of the major factors driving the Canada plasma fractionation market growth.  Additionally, increasing focus on strategic initiatives within the country also supports the market growth. Moreover, Canadian Blood Services (CBS) and governments are actively involved in securing a constant plasma supply, with a focus on opening dedicated plasma donor centers across the country. The CBS is collaborating with operating players to increase its self-sufficiency in Canada.

• For instance, according to data provided by Immunity Canada in January 2025, the plasma sufficiency for immunoglobulins has already improved from 12.8% (2020) to approximately 26%, with several new plasma centers planned for 2025.

MARKET RESTRAINTS:

Capacity Constraints and High Dependence on Global Suppliers to Restrict Market Growth

Capacity constraints and high dependence on global suppliers are one of the major limiting factors for the Canadian market growth. Even though the country is focusing on new initiatives for self-sufficiency, Canada still imports the majority of its plasma-derived medicines from international markets. This results in market vulnerability to international crises and other associated factors. This import dependence hampers market growth and keeps Canada vulnerable to global capacity constraints.

• For instance, according to data provided by Immunity Canada in January 2025, the plasma sufficiency for immunoglobulins is only around 26%.

MARKET OPPORTUNITIES:

Broader Adoption of Fibrinogen Concentrates and PCC in Surgery & Trauma Offers Significant Growth Opportunities

Broader adoption of fibrinogen concentrates and PCC in surgery & trauma is anticipated to offer promising growth opportunities in the market. Strong clinical evidence and increasing Health Canada approvals are accelerating the shift from cryoprecipitate/FFP to fibrinogen concentrate and PCC in cardiac surgery, trauma, and obstetric hemorrhage. As a result, operating players can shift their focus to capturing the untapped avenues of the market. Moreover, products such as Fibryga for congenital and acquired fibrinogen deficiency, and 4-factor PCCs for rapid warfarin reversal and perioperative bleeding, are increasingly being adopted in hospital protocols and blood management programs. All these factors are collectively expected to boost market growth in the near future.

MARKET CHALLENGES:

Competition from Alternative Therapies and Evolving Standards of Care Pose a Significant Challenge for Market

In several indication areas, plasma-derived products face competition from recombinant or non-factor therapies in Canada. As HTA bodies reassess older technologies, some use cases for plasma-derived factor concentrates or albumin may be displaced by novel drugs that offer better convenience or long-term outcomes, even if they are expensive. This results in slow growth in certain markets, in turn limiting the overall market growth.

CANADA PLASMA FRACTIONATION MARKET TRENDS:

Growth in Immunoglobulins is a Significant Trend Observed in Market

Canada has one of the highest usage rates for immunoglobulins globally. This is driven by strong guideline adoption in neurology, hematology, and immunology, and by off-label use in some refractory autoimmune conditions. With the strong clinical evidence for the use of immunoglobulins in various medical conditions, such as CIDP, MMN, ITP, and other indications, healthcare professionals tend to maintain chronic therapy rather than withdraw, which further supports market growth.

Download Free sample to learn more about this report.

Segmentation Analysis

By Product 

Wide Availability of Immunoglobulin (IG) Propelled Segment Growth

Based on the product, the market is divided into albumin, immunoglobulin (IG), coagulation factors (CF), protease inhibitors, and others. The immunoglobulin segment is sub-segmented into intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG). Whereas coagulation factor concentrates are categorized into factor IX, factor VIII, prothrombin complex concentrates, fibrinogen concentrates, and others. 

The immunoglobulin segment dominated the Canadian market, holding the largest market share, and is expected to maintain its dominance throughout the forecast period. This can be attributed to the significantly high usage of immunoglobulins for PIS and SID, coupled with an increasing number of strategic initiatives undertaken by market players.

• For instance, Canadian Blood Services (CBS) and Grifols have agreed on a long-term collaboration with the aim of boosting the country’s self-sufficiency and establishing the country’s first end-to-end domestic Ig supply chain.

Moreover, the albumin segment is expected to grow at a CAGR of 4.93% during the forecast period.

To know how our report can help streamline your business, Speak to Analyst

By Application

Rising Prevalence of Autoimmune Diseases Boosted Immunology & Neurology Segment Growth

Based on application, the market is divided into hematology, immunology & neurology, critical care, pulmonology, and others.

In 2024, the immunology & neurology segment captured the largest Canada plasma fractionation market share.  Furthermore, the segment is set to hold a 68.3% share in 2025. Rising prevalence of autoimmune and immunodeficiency diseases, expanding clinical trials of PDMPs for immunology, and increasing adoption of these products for therapeutic applications.

• For instance, Octapharma AG, Takeda Pharmaceutical Company Limited, and Grifols S.A. are some of the leading players that offer products for immunodeficiency.

In addition, the pulmonology segment is projected to grow at a CAGR of 4.36% during the study period. 

By End User

High Patient Volume Fueled Hospitals & Clinics Segment Expansion

Based on end user, the market is segmented into clinical research laboratories, hospitals & clinics, and others.

In 2024, the hospitals & clinics segment captured the largest Canada plasma fractionation market share. This dominance can be attributed to increasing patient volume opting for plasma-derived therapies, along with strong adoption by healthcare professionals of these therapies.  Furthermore, the hospitals & clinics segment is set to hold an 84.4% share in 2025.

In addition, the clinical research laboratories segment is projected to grow at a CAGR of 3.74% during the study period. 

COMPETITIVE LANDSCAPE

Key Industry Players:

Strategic Collaborations with Regulatory Bodies to Strengthen Their Market Positions

The Canada plasma fractionation market shows a highly consolidated nature, with key players such as CSL Behring LLC., Grifols S.A., and Octapharma AG accounting for the majority share of the market in 2024. High investments in research and development, an increasing focus on establishing new plasma collection centers, and a strong emphasis on collaborations and partnerships to strengthen brand presence are some key factors contributing to their dominance in the Canadian market.

Other notable plasma fractionation companies in the market are Takeda Pharmaceutical Company Limited and LFB. These companies are focusing on launching their products and expanding brand presence in the Canadian market.

LIST OF KEY CANADA PLASMA FRACTIONATION COMPANIES PROFILED:

• CSL Behring LLC. (U.S.)
• Octapharma AG (Switzerland)
• Grifols S.A. (Spain)
• Takeda Pharmaceutical Company Limited (Japan)
• Other Prominent Players

KEY INDUSTRY DEVELOPMENTS:

• March 2025: Takeda Canada Inc.’s HyQvia received expanded market authorization from Health Canada for chronic inflammatory demyelinating polyneuropathy (CIDP).
• January 2025: Takeda Canada Inc. announced that Héma-Québec will reimburse HyQvia for the treatment of immunodeficiencies in adult and pediatric patients over 2 years of age.
• June 2023: Canadian Plasma Resources and Grifols Group signed an agreement to secure plasma supply in Canada.
• September 2022: Canadian Blood Services and Grifols S.A. collaborated to expand the Country’s self-sufficiency for plasma.
• July 2022: Takeda Canada Inc. received expanded market authorization for HyQvia from Health Canada for primary humoral immunodeficiency (PI) and secondary humoral immunodeficiency (SI) in adult patients.

REPORT COVERAGE

The Canada plasma fractionation market analysis provides a detailed study of the market size & forecast by all the market segments included in the report. The report also provides insights into market dynamics and trends expected to drive the market during the forecast period. The Canada market report also comprises key aspects, such as an overview of technological advancements, product launches, insights on strategic partnerships, mergers & acquisitions, and key industry developments in Canada. The market forecast also provides a detailed competitive landscape, including market share and profiles of major industry players.

To gain extensive insights into the market, Download for Customization

Report Scope & Segmentation